Literature DB >> 19043448

Lacosamide.

Emilio Perucca1, Uma Yasothan, Gilbert Clincke, Peter Kirkpatrick.   

Abstract

In August 2008, lacosamide (Vimpat; UCB), was granted market authorization by the European Commission as an adjunctive therapy for partial-onset seizures with or without secondary generalization in patients with epilepsy. It was approved by the FDA as an adjunctive therapy for partial-onset seizures in October 2008.

Entities:  

Mesh：

Substances：

Year:  2008        PMID： 19043448     DOI： 10.1038/nrd2764

Source DB:  PubMed          Journal:  Nat Rev Drug Discov        ISSN： 1474-1776            Impact factor:   84.694


  29 in total

1.  In silico docking and electrophysiological characterization of lacosamide binding sites on collapsin response mediator protein-2 identifies a pocket important in modulating sodium channel slow inactivation.

Authors:  Yuying Wang; Joel M Brittain; Brian W Jarecki; Ki Duk Park; Sarah M Wilson; Bo Wang; Rachel Hale; Samy O Meroueh; Theodore R Cummins; Rajesh Khanna
Journal:  J Biol Chem       Date:  2010-06-09       Impact factor: 5.157

2.  The structure-activity relationship of the 3-oxy site in the anticonvulsant (R)-N-benzyl 2-acetamido-3-methoxypropionamide.

Authors:  Pierre Morieux; Christophe Salomé; Ki Duk Park; James P Stables; Harold Kohn
Journal:  J Med Chem       Date:  2010-08-12       Impact factor: 7.446

Review 3.  From laptop to benchtop to bedside: structure-based drug design on protein targets.

Authors:  Lu Chen; John K Morrow; Hoang T Tran; Sharangdhar S Phatak; Lei Du-Cuny; Shuxing Zhang
Journal:  Curr Pharm Des       Date:  2012       Impact factor: 3.116

Review 4.  Key factors in the discovery and development of new antiepileptic drugs.

Authors:  Meir Bialer; H Steve White
Journal:  Nat Rev Drug Discov       Date:  2010-01       Impact factor: 84.694

5.  Prevention of posttraumatic axon sprouting by blocking collapsin response mediator protein 2-mediated neurite outgrowth and tubulin polymerization.

Authors:  S M Wilson; W Xiong; Y Wang; X Ping; J D Head; J M Brittain; P D Gagare; P V Ramachandran; X Jin; R Khanna
Journal:  Neuroscience       Date:  2012-02-28       Impact factor: 3.590

6.  Chimeric derivatives of functionalized amino acids and α-aminoamides: compounds with anticonvulsant activity in seizure models and inhibitory actions on central, peripheral, and cardiac isoforms of voltage-gated sodium channels.

Authors:  Robert Torregrosa; Xiao-Fang Yang; Erik T Dustrude; Theodore R Cummins; Rajesh Khanna; Harold Kohn
Journal:  Bioorg Med Chem       Date:  2015-04-11       Impact factor: 3.641

7.  Merging Structural Motifs of Functionalized Amino Acids and α-Aminoamides Results in Novel Anticonvulsant Compounds with Significant Effects on Slow and Fast Inactivation of Voltage-gated Sodium Channels and in the Treatment of Neuropathic Pain.

Authors:  Yuying Wang; Sarah M Wilson; Joel M Brittain; Matthew S Ripsch; Christophe Salomé; Ki Duk Park; Fletcher A White; Rajesh Khanna; Harold Kohn
Journal:  ACS Chem Neurosci       Date:  2011-06-15       Impact factor: 4.418

8.  Identification of the benzyloxyphenyl pharmacophore: a structural unit that promotes sodium channel slow inactivation.

Authors:  Amber M King; Xiao-Fang Yang; Yuying Wang; Erik T Dustrude; Cindy Barbosa; Michael R Due; Andrew D Piekarz; Sarah M Wilson; Fletcher A White; Christophe Salomé; Theodore R Cummins; Rajesh Khanna; Harold Kohn
Journal:  ACS Chem Neurosci       Date:  2012-09-19       Impact factor: 4.418

9.  Fast- or slow-inactivated state preference of Na+ channel inhibitors: a simulation and experimental study.

Authors:  Robert Karoly; Nora Lenkey; Andras O Juhasz; E Sylvester Vizi; Arpad Mike
Journal:  PLoS Comput Biol       Date:  2010-06-17       Impact factor: 4.475

10.  (Biphenyl-4-yl)methylammonium chlorides: potent anticonvulsants that modulate Na+ currents.

Authors:  Hyosung Lee; Ki Duk Park; Xiao-Fang Yang; Erik T Dustrude; Sarah M Wilson; Rajesh Khanna; Harold Kohn
Journal:  J Med Chem       Date:  2013-07-03       Impact factor: 7.446
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.